Allogenic Bone-Marrow-Derived Mesenchymal Stem Cells: Side Effects, Uses & Monitoring
RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
- Data source
- FDA labeling via NIH DailyMed (label a4e0918f…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Frequently Asked Questions
What is Allogenic Bone-Marrow-Derived Mesenchymal Stem Cells used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Allogenic Bone-Marrow-Derived Mesenchymal Stem Cells?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Allogenic Bone-Marrow-Derived Mesenchymal Stem Cells require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Allogenic Bone-Marrow-Derived Mesenchymal Stem Cells.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.